Prolonging time to progression and survival in relapsed/refractory multiple myeloma

Published: June 10, 2009
Abstract Views: 185
PDF: 387
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Each year, over 16,500 new cases of multiple myeloma (MM) are diagnosed in the USA alone, making it the second most common type of haematological malignancy after non-Hodgkin’s lymphoma.1 Current treatment options for MM are non-curative, and the 5-year survival rate for all patients with MM has improved only slightly over the last 20−25 years, from 25% to 32%.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Sonneveld, P. (2009). Prolonging time to progression and survival in relapsed/refractory multiple myeloma. Hematology Meeting Reports (formerly Haematologica Reports), 2(14). https://doi.org/10.4081/hmr.v2i14.510